Skip to main content
SpringerLink
Log in

IncobotulinumtoxinA (Xeomin®) can produce antibody-induced therapy failure in a patient pretreated with abobotulinumtoxinA (Dysport®)

  • Neurology and Preclinical Neurological Studies - Short communication
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Abstract

IncobotulinumtoxinA has not produced a single case of antibody-induced therapy failure after 8 years of worldwide usage. We are reporting a patient with progressive hereditary juvenile onset generalised dystonia who was pretreated with abobotulinumtoxinA for 15 years, before she received incobotulinumtoxinA. To the fifth and sixth applications, she responded with complete therapy failure. Mouse hemidiaphragm assay testing revealed a maximal botulinum toxin antibody titre. Improved specific biological activity and lack of complexing proteins seem to reduce the antigenicity of incobotulinumtoxinA. However, this first ever report indicates that it does not eliminate it entirely.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Adib SF, Bigalke H, Dressler D (2010) Antigenicity differences between botulinum toxin drugs. Mov Disord 25(Suppl 2):S227 (Abstract)

    Google Scholar 

  • Dressler D (2002) Clinical features of secondary failure of botulinum toxin therapy. Eur Neurol 48:26–29

    Article  CAS  PubMed  Google Scholar 

  • Dressler D (2012) Five-year experience with incobotulinumtoxinA (Xeomin®): the first botulinum toxin drug free of complexing proteins. Eur J Neurol 19:385–389

    Article  CAS  PubMed  Google Scholar 

  • Dressler D, Bigalke H (2009) Pharmacology of botulinum toxin drugs. In: Truong D, Dressler D, Hallett M (eds) Manual of botulinum toxin therapy. Cambridge University Press, Cambridge

    Google Scholar 

Download references

Acknowledgments

DD received honoraria for consultations from Allergan, Eisai/Solstice, Ipsen, Merz and Syntaxin. He is a shareholder in Allergan. He holds patents in botulinum toxin research. FAS has nothing to disclose. HB is CEO of Toxogen.

Author information

Authors and Affiliations

  1. Movement Disorders Section, Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany

    Dirk Dressler & Fereshte Adib Saberi

  2. Institute of Toxicology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany

    Hans Bigalke

Authors
  1. Dirk Dressler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fereshte Adib Saberi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hans Bigalke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dirk Dressler.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dressler, D., Adib Saberi, F. & Bigalke, H. IncobotulinumtoxinA (Xeomin®) can produce antibody-induced therapy failure in a patient pretreated with abobotulinumtoxinA (Dysport®). J Neural Transm 121, 769–771 (2014). https://doi.org/10.1007/s00702-014-1165-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00702-014-1165-7

Keywords

Search

Navigation